+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risks and benefits of the treatment of heart failure. Current status



Risks and benefits of the treatment of heart failure. Current status



Drug Safety 6(4): 277-284



Congestive heart failure is an increasingly common patient problem. It is a multisystem disease that involves not only the heart but also the kidneys and neurohormonal systems. Any treatment for heart failure should address depressed contractility and exercise intolerance, as well as control compensatory mechanisms. There are many different approaches to the treatment of congestive heart failure: among the drugs used are diuretics, digitalis compounds, nitrates, calcium channel blockers, beta-blockers, beta-agonists, vasodilators, angiotensin-converting enzyme (ACE) inhibitors and the new phosphodiesterase inhibitors. The therapy usually involves a multiple drug treatment plan to achieve the maximum effect for the patient with the lowest incidence of side effects. Heart failure involves a large spectrum of patients with left ventricular dysfunction, and success at achieving treatment goals with these patients will vary with the severity of that symptom. A major concern is that increasing contractility may further damage the myocardium and shorten the survival of these patients, although there is as yet no evidence of such shortening. The new phosphodiesterase inhibitor drugs are an exciting development in the treatment of heart failure, because they add a dimension to the treatment for patients who are not sufficiently improved by a regimen of digoxin, diuretics and ACE inhibitors. Any new heart failure medication should be able to improve rest and exercise haemodynamics, maintain its benefits when given orally and result in an improved exercise capacity and quality of life, and prolonged survival.

(PDF emailed within 1 workday: $29.90)

Accession: 041279217

Download citation: RISBibTeXText

PMID: 1888443


Related references

Benefits, risks of heart failure drug questioned. The jury is still out on who needs nesiritide, a new heart failure drug, as well as what its risks are. Harvard Heart Letter 15(12): 3-3, 2005

Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease. Cardiology in Review 18(5): 240-250, 2011

Evidence review: emergency medical services treatment of patients with congestive heart failure/acute pulmonary edema: do risks outweigh benefits?. Journal of Emergency Nursing: Jen 31(1): 51-7; Quiz 118-9, 2005

Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. International Clinical Psychopharmacology 28(3): 145-155, 2013

Risks and benefits of Helicobacter pylori eradication: current status. Canadian Journal of Gastroenterology 16(1): 57-62, 2002

Risks and benefits of weight loss in heart failure. Heart Failure Clinics 11(1): 125-131, 2015

Methyl bromide: risks, benefits and current status in pest control. Reviews in pesticide toxicology(3): 21-44, 1995

Current status of the treatment of chronic heart failure--based on EBM. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 91 Suppl: 211-216, 2003

Treatment of congestive heart failure: Current status of use of digitoxin. European Journal of Clinical Investigation 31(Suppl. 2): 10-17, 2001

The biological treatment of heart failure: current status and prospect. Zhonghua Xin Xue Guan Bing Za Zhi 33(10): 873-874, 2005

Exercise training in congestive heart failure: risks and benefits. Progress in Cardiovascular Diseases 53(6): 419-428, 2011

Risks and Benefits of Risk Prediction in Acute Heart Failure. Jacc. Heart Failure 3(10): 748-750, 2016

Ultrafiltration Therapy for Heart Failure: Balancing Likely Benefits against Possible Risks. Clinical Journal of the American Society of Nephrology 11(8): 1463-1471, 2016

Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 44(6): 928-945, 1992